Integrative multi-omics analysis identifies a PTM-related immune signature and IRF9 as a driver in ccRCC
BackgroundClear cell renal cell carcinoma (ccRCC) exhibits marked heterogeneity and variable benefit from immune checkpoint inhibitors (ICIs). Post-translational modifications (PTMs) regulate immune signaling and tumor behavior, yet PTM-informed biomar…